A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Last updated: October 29, 2026
Sponsor: Rhythm Pharmaceuticals, Inc.
Overall Status: Completed

Phase

2

Condition

Diabetes Prevention

Obesity

Treatment

Placebo

LB54640

Bivamelagon

Clinical Study ID

NCT06046443
LG-MCCL005
  • Ages > 12
  • All Genders

Study Summary

The goal of this study was to determine how well LB54640 (also known as bivamelagon) worked and how safe it was in participants with Hypothalamic Obesity (HO). The study evaluated the effect of bivamelagon on safety, weight reduction, hunger, and quality of life in participants 12 years of age and older with HO. Participants took an oral daily dose of either bivamelagon (low, middle, or high dose) or placebo through Week 14. Eligible participants who consented to continue in the study after Week 14 took an oral daily dose of bivamelagon through Week 52.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  • Documented evidence of acquired hypothalamic obesity (HO)

  • Age 12 years and older

  • Weight gain associated with the hypothalamic injury and a body mass index (BMI) of ≥30 kg/m^2 for participants ≥18 years of age or BMI ≥95th percentile for age and sexfor participants <18 years of age

  • Male and female participants agreed to follow study contraception requirements anduse a highly effective form of contraception throughout the study and for 90 daysafter the study

Exclusion

Key Exclusion Criteria:

  • Weight loss >2% in the previous 3 months for participants ≥18 years of age or >2%reduction in BMI for participants <18 years of age

  • History of major surgical procedure within 30 days

  • HbA1c >10.9%

  • Fasting glucose level >270 mg/dL

  • Previous use of MC4R agonists

  • Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity withhypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumorsyndrome (ROHHADNET)

  • Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt orbehavior

  • History or close family history of skin cancer or melanoma

  • Clinically significant pulmonary, cardiac, or oncologic disease considered severeenough to interfere with the study and/or confound the results

Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design

Total Participants: 28
Treatment Group(s): 3
Primary Treatment: Placebo
Phase: 2
Study Start date:
July 11, 2024
Estimated Completion Date:
February 09, 2026

Connect with a study center

  • Birmingham Women's and Children's NHS Foundation Trust

    Birmingham, B15 2TG
    United Kingdom

    Site Not Available

  • University of Cambridge

    Cambridge, CB2 1TN
    United Kingdom

    Site Not Available

  • Great Ormond Street Hospital for Children

    London, WC1N 3JH
    United Kingdom

    Site Not Available

  • Children's Hospital Colorado

    Aurora, Colorado 80045
    United States

    Site Not Available

  • University of Iowa Children's Hospital

    Iowa City, Iowa 52242
    United States

    Site Not Available

  • Tufts Medical Center

    Boston, Massachusetts 02111
    United States

    Site Not Available

  • Columbia University

    New York, New York 10027
    United States

    Site Not Available

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina 27514
    United States

    Site Not Available

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma 73112
    United States

    Site Not Available

  • St. Jude Children's Research Hospital

    Memphis, Tennessee 38105
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.